605 related articles for article (PubMed ID: 18348306)
1. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
[TBL] [Abstract][Full Text] [Related]
2. Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.
Oikawa M; Yoshiura K; Kondo H; Miura S; Nagayasu T; Nakashima M
Radiat Oncol; 2011 Dec; 6():168. PubMed ID: 22152285
[TBL] [Abstract][Full Text] [Related]
3. Genomic instability in the epidermis induced by atomic bomb (A-bomb) radiation: a long-lasting health effect in A-bomb survivors.
Naruke Y; Nakashima M; Suzuki K; Kondo H; Hayashi T; Soda M; Sekine I
Cancer; 2009 Aug; 115(16):3782-90. PubMed ID: 19517458
[TBL] [Abstract][Full Text] [Related]
4. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
Park K; Kwak K; Kim J; Lim S; Han S
Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors.
Goodman MT; Cologne JB; Moriwaki H; Vaeth M; Mabuchi K
Prev Med; 1997; 26(1):144-53. PubMed ID: 9010910
[TBL] [Abstract][Full Text] [Related]
6. Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: association with radiation exposure.
Nakashima M; Kondo H; Miura S; Soda M; Hayashi T; Matsuo T; Yamashita S; Sekine I
Cancer Sci; 2008 Jan; 99(1):87-92. PubMed ID: 17979995
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
8. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
[TBL] [Abstract][Full Text] [Related]
9. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
10. Male breast cancer incidence among atomic bomb survivors.
Ron E; Ikeda T; Preston DL; Tokuoka S
J Natl Cancer Inst; 2005 Apr; 97(8):603-5. PubMed ID: 15840883
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of lung tumour mortality risk in the Japanese A-bomb survivors and in the Colorado Plateau uranium miners: support for the ICRP lung model.
Little MP
Int J Radiat Biol; 2002 Mar; 78(3):145-63. PubMed ID: 11869470
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
13. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
14. Cancer and non-cancer effects in Japanese atomic bomb survivors.
Little MP
J Radiol Prot; 2009 Jun; 29(2A):A43-59. PubMed ID: 19454804
[TBL] [Abstract][Full Text] [Related]
15. Profiles of non-cancer diseases in atomic bomb survivors.
Kodama K; Fujiwara S; Yamada M; Kasagi F; Shimizu Y; Shigematsu I
World Health Stat Q; 1996; 49(1):7-16. PubMed ID: 8896251
[TBL] [Abstract][Full Text] [Related]
16. c-myc amplifications in primary breast carcinomas and their local recurrences.
Aulmann S; Adler N; Rom J; Helmchen B; Schirmacher P; Sinn HP
J Clin Pathol; 2006 Apr; 59(4):424-8. PubMed ID: 16497871
[TBL] [Abstract][Full Text] [Related]
17. Amplification of HER2 is a marker for global genomic instability.
Ellsworth RE; Ellsworth DL; Patney HL; Deyarmin B; Love B; Hooke JA; Shriver CD
BMC Cancer; 2008 Oct; 8():297. PubMed ID: 18854030
[TBL] [Abstract][Full Text] [Related]
18. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer among atomic bomb survivors--the relationship of prognosis to pathologic findings.
Tokunaga M
Acta Pathol Jpn; 1979 Mar; 29(2):197-209. PubMed ID: 552793
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
